gimli

NOVARTIND stock AI analysis

NOVARTIND Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

NOVARTIS INDIA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available NOVARTIND price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive NOVARTIND stock page

Price

₹1,722.40

1W return

-6.79%

1M return

-12.35%

3M return

+5.30%

6M return

+67.14%

1Y return

n/a

Market cap

₹4,252.74 cr

43.50

5.20

ROE

+12.20%

ROCE

+12.92%

RSI

40.81

Turnover

₹4.70 cr

Why it can matter in screens

Momentum: NOVARTIND is below 50DMA, below 200DMA; RSI is 40.81.
Returns: 1D +0.27%, 1W -6.79%, 1M -12.35%, 3M +5.30%, 1Y n/a.
Trend levels: 52W high ₹2,588.80, 52W low ₹1,272.10, off high -33.47%.
Liquidity: latest turnover is ₹4.70 cr; volume vs 20D is +0.71%.
Valuation/profitability: PE 43.50, PB 5.20, ROE +12.20%, ROCE +12.92%.
Growth: 3Y sales CAGR -1.35%, 3Y profit CAGR -3.40%.

Quick Answers

What is the latest NOVARTIND stock price?

The latest stored price for NOVARTIND is Rs 1,722.40 as of 2026-11-03.

Is NOVARTIND above its 50DMA and 200DMA?

NOVARTIND is below 50DMA, below 200DMA. The latest 50DMA is 1,856.76 and the latest 200DMA is n/a.

What are NOVARTIND PE, ROE and ROCE?

NOVARTIND has PE 43.50, ROE +12.20%, and ROCE +12.92% in Gimli's latest available snapshot.

How has NOVARTIND performed recently?

NOVARTIND has returned -12.35% over 1 month, +5.30% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-06-30	103.81 cr	43.65 cr	32.21 cr	13.05
2026-03-31	90.55 cr	30.63 cr	25.25 cr	10.23
2025-12-31	85.90 cr	31.11 cr	16.09 cr	6.52
2025-09-30	99.73 cr	33.28 cr	24.22 cr	9.81
2025-06-30	87.55 cr	37.85 cr	27.62 cr	11.19
2025-03-31	83.88 cr	34.54 cr	29.30 cr	11.87
2024-12-31	93.00 cr	36.18 cr	25.45 cr	nan
2024-09-30	87.10 cr	28.28 cr	20.41 cr	8.27

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	354.33 cr	132.87 cr	93.18 cr	37.74
2025-03-31	356.27 cr	133.38 cr	100.90 cr	40.87
2024-03-31	334.04 cr	126.94 cr	85.19 cr	34.50
2023-03-31	369.11 cr	123.19 cr	103.36 cr	41.86
2022-03-31	433.06 cr	10.66 cr	-3.72 cr	-1.51

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	978.27 cr	52.50 cr	3.21 cr	817.83 cr
2025-03-31	947.81 cr	52.07 cr	5.06 cr	784.96 cr
2024-03-31	924.93 cr	44.98 cr	6.97 cr	744.82 cr
2023-03-31	982.94 cr	19.42 cr	21.51 cr	775.66 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	46.73 cr	46.39 cr	n/a
2025-03-31	74.57 cr	74.57 cr	n/a
2024-03-31	113.40 cr	113.40 cr	n/a
2023-03-31	44.80 cr	44.49 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

No recent data available.

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	424,658.30 cr	35.053345	+15.50%	+3.72%
DIVISLAB	DIVI S LABORATORIES LTD	267,167.60 cr	91.684145	+18.37%	+47.91%
TORNTPHARM	TORRENT PHARMACEUTICALS L	157,377.11 cr	74.094685	+16.87%	+28.16%
LAURUSLABS	LAURUS LABS LIMITED	125,408.69 cr	114.827348	+21.77%	+138.16%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	124,833.39 cr	27.818646	+16.04%	+26.46%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	121,354.29 cr	57.614911	+22.62%	+7.87%
DRREDDY	DR. REDDY S LABORATORIES	113,923.95 cr	40.698752	+7.80%	+14.41%
CIPLA	CIPLA LTD	112,841.65 cr	38.950805	+8.80%	-7.58%

Try these prompts

Analyze NOVARTIS INDIA with valuation, momentum and industry peers
Compare NOVARTIND with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-11-03. Not investment advice.